Auna 1Q26 Results Confirm Mexico Still Stalled, Covenant Pressure Mounts

What happened

Auna reported 1Q26 results with Mexico utilization flat at 39.4% (vs. 39.8% a year ago) and emergency treatments down 2.3% YoY, while Peru and Colombia utilization improved. Consolidated performance likely fell near the low end of FY26 guidance, but the lack of Mexico inflection keeps the recovery narrative unproven. Net leverage at 3.64x and interest coverage barely above the 1.75x covenant leave minimal room for error, and any further deterioration could trigger liquidity constraints. Management's full-year growth guidance of 10–14% FX-neutral revenue and Adjusted EBITDA now hinges entirely on Mexico volume acceleration in 2H26, a high-risk assumption. At 6.1x EV/EBITDA, the stock prices in a recovery that remains absent, offering no margin of safety given tight covenants and execution risk.

Implication

If Mexico fails to recover by 3Q26, the equity faces covenant-driven restructuring risk; only consider accumulating below $4.50 to capture a potential turnaround with adequate downside protection.

Thesis delta

1Q26 results confirm Mexico's recovery is not materializing, pushing the expected inflection point to 2H26 and increasing the probability of covenant breach. The thesis shifts from 'potential recovery' to a 'show-me' stance, requiring visible volume improvement by 3Q26 to avoid a bear scenario.